Lexicon Pharmaceuticals Statistics
Total Valuation
LXRX has a market cap or net worth of $1.13 billion. The enterprise value is $1.02 billion.
Important Dates
The next estimated earnings date is Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LXRX has 444.20 million shares outstanding. The number of shares has increased by 6.70% in one year.
| Current Share Class | 444.20M |
| Shares Outstanding | 444.20M |
| Shares Change (YoY) | +6.70% |
| Shares Change (QoQ) | +10.13% |
| Owned by Insiders (%) | 1.47% |
| Owned by Institutions (%) | 29.23% |
| Float | 262.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.26 |
| Forward PS | 63.30 |
| PB Ratio | 5.33 |
| P/TBV Ratio | 7.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.79, with a Debt / Equity ratio of 0.28.
| Current Ratio | 18.79 |
| Quick Ratio | 18.43 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.99 |
Financial Efficiency
Return on equity (ROE) is -16.01% and return on invested capital (ROIC) is -6.18%.
| Return on Equity (ROE) | -16.01% |
| Return on Assets (ROA) | -5.35% |
| Return on Invested Capital (ROIC) | -6.18% |
| Return on Capital Employed (ROCE) | -9.36% |
| Weighted Average Cost of Capital (WACC) | 10.17% |
| Revenue Per Employee | $859,790 |
| Profits Per Employee | -$322,086 |
| Employee Count | 81 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 17.17 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +183.81% in the last 52 weeks. The beta is 1.07, so LXRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.07 |
| 52-Week Price Change | +183.81% |
| 50-Day Moving Average | 1.98 |
| 200-Day Moving Average | 1.55 |
| Relative Strength Index (RSI) | 76.21 |
| Average Volume (20 Days) | 4,133,536 |
Short Selling Information
The latest short interest is 25.43 million, so 5.72% of the outstanding shares have been sold short.
| Short Interest | 25.43M |
| Short Previous Month | 26.21M |
| Short % of Shares Out | 5.72% |
| Short % of Float | 9.68% |
| Short Ratio (days to cover) | 12.78 |
Income Statement
In the last 12 months, LXRX had revenue of $69.64 million and -$26.09 million in losses. Loss per share was -$0.07.
| Revenue | 69.64M |
| Gross Profit | 65.55M |
| Operating Income | -24.23M |
| Pretax Income | -26.09M |
| Net Income | -26.09M |
| EBITDA | -23.67M |
| EBIT | -24.23M |
| Loss Per Share | -$0.07 |
Full Income StatementBalance Sheet
The company has $170.66 million in cash and $57.71 million in debt, giving a net cash position of $112.95 million or $0.25 per share.
| Cash & Cash Equivalents | 170.66M |
| Total Debt | 57.71M |
| Net Cash | 112.95M |
| Net Cash Per Share | $0.25 |
| Equity (Book Value) | 202.86M |
| Book Value Per Share | 0.48 |
| Working Capital | 176.13M |
Full Balance SheetCash Flow
| Operating Cash Flow | -38.80M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 555,000 |
| Net Borrowing | -53.00M |
| Free Cash Flow | -38.80M |
| FCF Per Share | -$0.09 |
Full Cash Flow StatementMargins
Gross margin is 94.12%, with operating and profit margins of -34.79% and -37.46%.
| Gross Margin | 94.12% |
| Operating Margin | -34.79% |
| Pretax Margin | -37.46% |
| Profit Margin | -37.46% |
| EBITDA Margin | -33.99% |
| EBIT Margin | -34.79% |
| FCF Margin | n/a |
Dividends & Yields
LXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.70% |
| Shareholder Yield | n/a |
| Earnings Yield | -2.30% |
| FCF Yield | -3.43% |
Analyst Forecast
The average price target for LXRX is $3.77, which is 47.84% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.77 |
| Price Target Difference | 47.84% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 15.21% |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 21, 2015. It was a reverse split with a ratio of 1:7.
| Last Split Date | May 21, 2015 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
LXRX has an Altman Z-Score of -5.81 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.81 |
| Piotroski F-Score | 4 |